A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas

Dora Dias-Santagata, Quynh Lam, Kristin Bergethon, Gabrielle M. Baker, A. John Iafrate, Dinesh Rakheja, Mai P. Hoang

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Metastasizing adnexal carcinomas are rare; thus, currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. We performed immunohistochemistry (epidermal growth factor receptor (EGFR), HER2, and CD117), EGFR and ERBB2 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot genotyping (testing for recurrent mutations in 15 cancer genes including BRAF, EGFR, KRAS, PIK3CA, and TP53) on primary tumors and corresponding metastases of 14 metastasizing adnexal carcinomas (three apocrine, six eccrine, two hidradenocarcinomas, two porocarcinomas, and one aggressive digital papillary adenocarcinoma). Metastasis to regional lymph node was most common, followed by skin and then lungs. Follow-up was available in 12 patients (5 months to 8 years) with 1 died of widespread metastases. Although EGFR overexpression was a prevalent feature in this cohort, seen in 7/11 (64%) primary tumors and 10/14 (71%) metastases; FISH for EGFR gene amplification was negative in 9 tested primary tumors and 12 metastases. FISH of the one primary tumor and three metastases with 2 HER2 overexpression revealed a low level of ERBB2 gene amplification in one apocrine carcinoma and corresponding metastasis. CD117 expression was seen only in rare cases. PIK3CA (2/12, 17%) and TP53 (3/12, 25%) mutations were detected in two (one hidradenocarcinoma, one porocarcinoma) and three (one eccrine, one hidradenocarcinoma, and one aggressive digital papillary adenocarcinoma) cases, respectively. The role of EGFR inhibitor therapy in metastasizing adnexal carcinomas with protein overexpression remains unclear. Targeted therapy including PI3K pathway inhibitors might be a potential treatment for rare cases of adnexal carcinomas with metastases.

Original languageEnglish (US)
Pages (from-to)974-982
Number of pages9
JournalModern Pathology
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2011

Keywords

  • EGFR
  • PIK3CA
  • TP53
  • adnexal neoplasm
  • gene mutation
  • metastasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas'. Together they form a unique fingerprint.

  • Cite this

    Dias-Santagata, D., Lam, Q., Bergethon, K., Baker, G. M., Iafrate, A. J., Rakheja, D., & Hoang, M. P. (2011). A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Modern Pathology, 24(7), 974-982. https://doi.org/10.1038/modpathol.2011.48